Posts tagged H.C. Wainwright


Sorrento Therapeutics Inc (SRNE) Has Competitive Advantage to Claim Meaningful Share in Lidocaine Patch Market, Cheers H.C. Wainwright

Analyst spotlights a compelling commercial future ahead for Sorrento’s ZTlido in post-herpetic neuralgia.

Read more

Here’s Why H.C. Wainwright Just Cut the Price Target for Synergy Pharmaceuticals Inc (SGYP) by 50%

Ram Selvaraju slashes his target to $8 on slower Trulance ramp.

Read more

Capricor Therapeutics Inc (CAPR) Investors Throw Bullish Parade After H.C. Wainwright Boosts Price Target

Analyst spotlights a compelling path forward for DMD program and looks to key catalysts in fourth quarter.

Read more

Just How Frustrated Should Investors Be with Advaxis, Inc. (ADXS)? H.C. Wainwright Remains Bullish

Analyst defends ADXS’ new “astute” clinical development strategy to re-focus on leading product assets.

Read more

Rexahn Pharmaceuticals, Inc. (RNN) Phase 2a Update in Muscle Invasive Bladder Cancer Shows Promise, Cheers H.C. Wainwright

RNN’s Phase 2a results have analyst optimistic on RX-3117 drug for patients running out of options.

Read more

Valeant Pharmaceuticals Intl Inc (VRX): Tampa Resolution to Pave the Way for FDA Approvals

H.C. Wainwright Is Looking Ahead to Ophthalmology Product Approvals as Tampa Facility Issues Addressed

Read more

Will Pluristem Therapeutics Inc.’s (PSTI) PLX-R18 Help Treat Acute Radiation Syndrome? H.C. Wainwright Weighs in

Analyst Swayampakula Ramakanth of H.C. Wainwright is out with a research note on Pluristem Therapeutics …

Read more

H.C. Wainwright Sees 230% Upside Potential For Sophiris Bio Inc (SPHS) As Prostate Cancer Drug Enters Phase 2b Trial

Analyst Joseph Pantginis of H.C. Wainwright is optimistic regarding the pace of Sophiris Bio Inc’s (NASDAQ:SPHS) Phase 2b study …

Read more

Ocular Therapeutix Inc (OCUL) Gets A Bullish Vote Following 2Q:17 Update

Ocular Therapeutix Inc (NASDAQ:OCUL) shares are on a roughly 4% dip today after the biotech …

Read more

Irrational Opioid Crisis Volatility Nipping at AcelRx Pharmaceuticals Inc (ACRX) Presents Stellar Entry Point

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) investors are getting enthusiastic again after the biotech firm’s Phase 3 …

Read more